Navigation Links
NIH names leadership, research units for restructured HIV/AIDS

Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Total funding for the networks' leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.

"With much recent progress, this is a very exciting time in HIV/AIDS research. The next seven years will be a critical period as we pursue the now-achievable goal of an AIDS-free generation, one in which new infections and deaths from AIDS are very rare," said NIAID Director Anthony S. Fauci, M.D. "These new awards position us to build upon the success of our current HIV/AIDS clinical research infrastructure by creating a broader, more flexible, and more collaborative approach to domestic and global HIV/AIDS research priorities."

Planning for restructuring of the HIV/AIDS clinical trials networks began in 2010 and involved extensive consultations with researchers, clinicians, nurses, patient advocates and other activists, and people living with HIV or at risk for infection. The new awards are intended to expand the scope of the network's current activities to include the treatment and prevention of other infectious diseases, notably tuberculosis and hepatitis, which are the most significant co-infections for people who are infected with HIV or at risk for infection.

The new structure is designed to increase collaboration across the networks, create transparent mechanisms for network leaders to solicit and support ideas from the research community, and develop a means for external researchers to tap into the networks' clinical trial infrastructure and capacity.

Leadership Groups

Each newly awarded leadership group will be led by one or more principal investigators and include a core operations group, a central laboratory and a statistical and data management center. The following principal investigators and institutions will lead the five HIV/AIDS networks:

  • AIDS Clinical Trials Group (ACTG): Daniel R. Kuritzkes, M.D.; Brigham and Women's Hospital, Boston
  • HIV Prevention Trials Network (HPTN): Wafaa El-Sadr, M.D., M.P.H., and Myron Cohen, M.D.; Family Health International, Durham, N.C.
  • HIV Vaccine Trials Network (HVTN): Lawrence Corey, M.D., Glenda Gray, M.B.B.Ch., and Scott Hammer, M.D.; The Fred Hutchinson Cancer Research Center, Seattle
  • International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network: Jay Brooks Jackson, M.D.; Johns Hopkins University School of Medicine, Baltimore
  • Microbicide Trials Network (MTN): Sharon L. Hillier, Ph.D. and Ian Michael McGowan, M.D., Ph.D.; Magee-Womens Research Institute and Foundation, Pittsburgh

The leadership groups will have overall responsibility for developing, implementing and adapting clinical research agendas to address NIAID's HIV/AIDS scientific priorities, including

  • Therapeutics for HIV/AIDS and HIV-associated infections in adults (including HIV cure, as well as co-occurring noninfectious and infectious diseases, including hepatitis and tuberculosis).
  • HIV/AIDS and HIV-associated infections in children and mothers
  • Integrated strategies to prevent HIV infection
  • Vaccines to prevent HIV infection
  • Microbicides to prevent HIV infection

They are expected to direct, coordinate and conduct NIAID-funded HIV/AIDS clinical research worldwide in close collaboration with one another, NIAID, other partner NIH institutes, and industry, foundations, and non-governmental research organizations.

Clinical Trials Units

In addition to the leadership groups, NIAID also named the 37 CTUs responsible for implementing the scientific agendas of the networks. Each CTU includes an administrative component with performance and resource management responsibilities and clinical research sitesthe hospitals, outpatient clinics, health maintenance organizations, community health centers, private physician practices and clinics where clinical trials are conducted. Each CTU will affiliate with at least two of the five HIV/AIDS networks and have the option to work with other NIAID clinical networks, including NIAID's newly developed Antibacterial Resistance Clinical Research Network.

A principal investigator will lead each of the CTUs. For a complete list of those principal investigators and their affiliations, see the related table for details.

The U.S.-based CTUs will be located in Alabama, California, the District of Columbia, Florida, Georgia, Illinois, Maryland, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, Tennessee, Washington state and Puerto Rico. The CTUs located outside of the United States are in Botswana, Brazil, China, Haiti, India, Kenya, Malawi, Mozambique, Peru, South Africa, Tanzania, Thailand, Switzerland, Uganda, Zambia, and Zimbabwe.

For a complete list of the 108 clinical research sites, see the related table for details.

Through the coordination of the NIH Office of AIDS Research, the other NIH institutes that will collaborate with one or more of the HIV/AIDS clinical trials networks and NIAID include the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute of Dental and Craniofacial Research, the National Institute of Neurological Disorders and Stroke and the National Cancer Institute.

For more details about the network leadership groups, the CTUs and clinical research sites, see the Restructuring the NIAID Clinical Trials Networks website.


Contact: Jennifer Routh
NIH/National Institute of Allergy and Infectious Diseases

Related medicine news :

1. Kessler Foundation names Dr. John Whyte recipient of Foundations 2nd Annual DeLisa Award
2. US Drug Watchdog Now Urges All Recalled DePuy ASR Hip Implant Recipients Call Them For The Names Of The Best Attorneys Out Of Fear The Recipients Will Get Nothing
3. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
4. Mesothelioma Victims Center Now Offers A US Navy Veteran Individual Or Family Dealing With Mesothelioma The Names Of The Best Mesothelioma Attorneys--Quality Matters
5. US Drug Watchdog Now Offers Victims of All Metal Hip Implant Failure the Names of the Best Attorneys & Calls Metal Hip Implants a Train Wreck with Up to 500,000 Victims
6. Mesothelioma Victims Center Now Offers All Families Dealing With A Mesothelioma Diagnosis The Names Of The Best Mesothelioma Attorneys-No Other Group Offers this Service
7. Mesothelioma Victims Center Urges US Navy Veterans or Anyone with Mesothelioma to Call Them for the Names of the Best Mesothelioma Attorneys in the US-Quality Matters
8. US Drug Watchdog Says Its Critical All DePuy Pinnacle Hip Implant Recipients Know The Symptoms Of A Failure And They Offer The Names Of The Best Attorneys For Victims
9. The Mesothelioma Victims Center Now Offers The Names Of the Best Mesothelioma Attorneys To Senior Citizens Diagnosed With Mesothelioma Because They Have Rights Too
10. Mesothelioma Victims Center Now Urges US Navy Veterans Or Individuals With Mesothelioma To Call Them For The Names Of The Best Mesothelioma Attorneys & Treatment Options
11. President Obama names SF State math professor a top young scientist
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology: